Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 216-885-3 | CAS number: 1689-99-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Immunotoxicity
Administrative data
Description of key information
Key, M-410294-01-1; subacute immunotoxicity (mouse, U.S. EPA test guideline, GLP):
NOAEL (systemic): 300 ppm (corresponding to 49 mg/kg bw/day, highest dose tested)
NOAEL (immunotoxicity): 300 ppm (corresponding to 49 mg/kg bw/day, highest dose tested)
Key value for chemical safety assessment
Effect on immunotoxicity: via oral route
Link to relevant study records
- Endpoint:
- immunotoxicity: short-term oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 12 Jan - 31 Mar 2011
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.7800
- Version / remarks:
- adopted 1998
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- mouse
- Strain:
- C57BL
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River laboratories, France
- Age at study initiation: 7 weeks
- Weight at study initiation: 20.3 - 24.3 g
- Housing: individually in suspended, stainless steel, wire-mesh cages
- Diet: Certified rodent powdered and irradiated diet A04CP1-10 from S.A.F.E. (Scientific Animal Food and Engineering, Augy, France), ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 12 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24
- Humidity (%): 40 - 70
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: 12 Jan 2011 To: 22 Feb 2011 - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST ITEM
DIET PREPARATION
- Rate of preparation of diet (frequency): once for each concentration
- Mixing appropriate amounts with: The appropriate amount of the test item ground to a fine powder, which was added to the diet.
- Storage temperature of food: when not in use, the diet was stored at -20 °C
CYCLOPHOSPHAMIDE
PREPARATION OF DOSING SOLUTIONS:
- Lot/Batch Nr: 068K1131
- Appearance: white powder
- Purity: 98.0%
- Storage: 5 °C
- Date of Analysis: August 2008
- Expiry date: August 2011
- Route of exposure: gavage
-Time schedule: daily
- Concentration: 7.5 mg/kg bw/day
- Volume: 5 mL/kg body weight
Preparation:
- Rate of preparation (frequency): twice
Procedure: The dosing formulation of cyclophosphamide was prepared by suspending the substance in sterilized water to produce the required dosing concentration.
Storage: +5 °C in the dark when not in use - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Homogeneity of the test substance in the diet was verified for the lowest and highest administered concentration before the start of the study. Dietary levels of the test substance were verified for each concentration. The homogeneity and concentration results ranged between 97 and 103% of the nominal concentration and were therefore within in-house target range of 85 and 115% for a dietary mix. Stability of the test item in the diet was analyzed for the highest and lowest dietary concentration after samples were kept at room temperature for 3 days. The test substance was stable over this period.
The homogeneity of the positive control was proven on the first formulation. Homogeneity and concentration of cyclophosphamide, formulations ranged from 99% to 101% of the nominal concentration and were therefore within in-house target range of 90 and 110% for a solution. The stability was verified in previous studies at concentrations of 0.1 to 3 g/L for a time period which covers the period of storage and usage for the current study. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- continuously via the diet (treatment with test substance),
daily, 7 days/week (positive control) - Dose / conc.:
- 30 ppm
- Remarks:
- corresponding to 5 mg/kg bw/day
- Dose / conc.:
- 100 ppm
- Remarks:
- corresponding to 16 mg/kg bw/day
- Dose / conc.:
- 300 ppm
- Remarks:
- corresponding to 49 mg/kg bw/day
- No. of animals per sex per dose:
- 10 males
- Control animals:
- yes, plain diet
- Details on study design:
- This immunotoxicity study was performed in mice because studies in mice and rats have revealed no evidence of immunotoxicity and rats are less sensitive than mice to the general toxicological effects of the test substance. Male mice were more sensitive than female mice in the previously conducted 90-day feeding study and were therefore used for this study.
Sheep Red Blood Cell (SRBC) ADMINISTRATION
SRBC
- Supplier: BioMérieux
- Reference Number: 72141
- Storage: 2 - 8 °C
-Time schedule: Day 26
- Anesthesia: Yes (Isoflurane (Baxter, Maurepas, France))
- number of cells injected: 1 * 10^8 SRBC/animal
- Procedure: On the day of injection, Sheep Red Blood Cells were washed in PBS (Phosphate Buffered Saline), counted using a cell counting instrument (Siemens Advia 120) and diluted in PBS in order to obtain a 1 x 10^9 cells/mL preparation. SRBC preparation was kept on ice until use. All animals of all groups were injected (tail vein, 0.1 mL/animal) with SRBC preparation. - Observations and clinical examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: twice daily (once daily on weekends and public holidays)
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: at least weekly during the treatment period
BODY WEIGHT: Yes
- Time schedule for examinations: weekly during acclimation and treatment and before necropsy.
FOOD CONSUMPTION AND COMPOUND INTAKE:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
WATER CONSUMPTION AND COMPOUND INTAKE: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: No
URINALYSIS: No - Sacrifice and pathology:
- Surviving animals were sacrificed by exsanguination while under deep anesthesia (Isoflurane inhalation).
GROSS PATHOLOGY: Yes
The necropsy included the examination of all major organs, tissues and body cavities. Macroscopic abnormalities were recorded but not sampled.
Organ weight was recorded for: Spleen and thymus.
HISTOPATHOLOGY: No - Cell viabilities:
- No data
- Humoral immunity examinations:
- ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA): Yes
- Method: Rat Anti-Sheep Red Blood Cell IgM ELISA kits from Life Diagnostics (West Chester, PA 19380 – USA)
- Dose groups: all
- No. of animals: 10/dose group (all animals) - Specific cell-mediated immunity:
- No data
- Non-specific cell-mediated immunity:
- No data
- Other functional activity assays:
- None
- Other examinations:
- None
- Positive control:
- Yes, one group of animals received 7.5 mg/kg bw/day cyclophosphamide (immunosuppressive agent) in sterilized water by gavage.
Cyclophosphamide: batch number 068K1131: a white powder, 98.0% purity - Statistics:
- Mean and standard deviation were calculated for each group and time period.
Body weight change, terminal body weight, absolute and relative organ weight parameters:
To analyze the differences between the control and the positive group cyclophosphamide, an F test was performed. If this showed significant differences, a 2-sided modified t-test followed. If no significance was found, a 2-sided T-test was performed.
To compare control and test substance groups, group variances were analyzed with the Bartlett test followed with an Analysis of Variance (ANOVA) and a 2-sided
Dunnett's test (if needed) when variance was equal and a Kruskal-Wallis and 2-sided Dunn test (if needed) when variance differed.
Body weight and average food consumption/day parameters:
The comparison between the control and positive group was similar to the above described, only that the data was transformed using the log transformation if the F test showed a significant difference.
Then, the procedure was repeated on the transformed data.
The comparison between the control and test substance groups was also similar to the above described, only that the data was transformed using the log transformation if the Bartlett test showed a significant difference. Then, the procedure was repeated on the transformed data and followed as described above.
If one or more group variance (s) equaled 0, means were compared using non-parametric procedures.
Immunological parameters:
The control and positive group were compared using the 2-sided Mann-Whitney test.
The control and test substance group were compared with the Kruskal-Wallis-test. If a significant difference was found, the 2-sided Dunn Test was used.
Significance in all of the tests was defined as p ≤ 0.05. - Clinical signs:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related signs observed in the treatment groups and positive control group.
- Dermal irritation (if dermal study):
- not examined
- Description (incidence and severity):
- not applicable
- Mortality:
- no mortality observed
- Description (incidence):
- not applicable
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- There were no differences regarding body weight and body weight changes in the treatment groups and positive control group compared to the control group.
One animal in the 30 ppm group showed body weight loss between study days 22 and 29. This was considered not to be treatment-related as it was not found in any other animal. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There were no differences regarding food consumption in the treatment groups and positive control group compared to the control group.
- Food efficiency:
- not examined
- Description (incidence and severity):
- not applicable
- Water consumption and compound intake (if drinking water study):
- not examined
- Description (incidence and severity):
- not applicable
- Ophthalmological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Haematological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Clinical biochemistry findings:
- not examined
- Description (incidence and severity):
- not applicable
- Endocrine findings:
- not examined
- Description (incidence and severity):
- not applicable
- Urinalysis findings:
- not examined
- Description (incidence and severity):
- not applicable
- Behaviour (functional findings):
- not examined
- Description (incidence and severity):
- not applicable
- Immunological findings:
- no effects observed
- Description (incidence and severity):
- Please refer to 'Humoral immunity examinations'.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no differences regarding terminal body weight and organ weights in the treatment groups and positive control group compared to the control group.
Positive control (Cyclophosphamide)
Mean absolute and relative spleen (-23 to -25%) and thymus (-24% and -26%) weights were decreased compared to controls.
Summarized results can be found in Attachment 2 in the attached background material. - Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- There were no differences between control and treatment groups. In the positive control group, atrophic/small spleen and/or thymus were noted in 7/10 and 8/10 animals, respectively.
- Neuropathological findings:
- not examined
- Description (incidence and severity):
- not applicable
- Histopathological findings: non-neoplastic:
- not examined
- Description (incidence and severity):
- not applicable
- Histopathological findings: neoplastic:
- not examined
- Description (incidence and severity):
- not applicable
- Other effects:
- not examined
- Description (incidence and severity):
- not applicable
- Cell viabilities:
- not examined
- Description (incidence and severity):
- not applicable
- Humoral immunity examinations:
- no effects observed
- Description (incidence and severity):
- For the test substance, no statistically significant differences were noticed as compared to the concurrent control group. Slightly lower mean anti-SRBC IgM concentrations as compared to the control group were observed at 300 (-36%) and 100 ppm (-23%). However, only few values (4/10 and 1/10, respectively) were lower than the lowest individual value of the control group. Therefore these changes were considered not to be relevant.
Positive control (Cyclophosphamide)
Anti-SRBC IgM mean concentration was statistically significantly lower as compared to the control group (-76%, p =<0.01), proving the sensitivity of the assay to identify an immunosuppressive agent.
Summarized results can be found in Attachment 1 in the attached background material. - Specific cell-mediated immunity:
- not examined
- Description (incidence and severity):
- not applicable
- Non-specific cell-mediated immunity:
- not examined
- Description (incidence and severity):
- not applicable
- Other functional activity assays:
- not examined
- Description (incidence and severity):
- not applicable
- Other findings:
- not examined
- Description (incidence and severity):
- not applicable
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Immunotoxicity
- Effect level:
- 300 ppm
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: No adverse effects were observed up to the highest dose level.
- Remarks on result:
- other: corresponding to an actual dose ingested of 49 mg/kg bw/day.
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- general toxicity
- Effect level:
- 300 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects were observed up to the highest dose level.
- Remarks on result:
- other: corresponding to an actual dose ingested of 49 mg/kg bw/day.
- Key result
- Critical effects observed:
- no
- Conclusions:
- The study assessed the effects of the test item on the immune system in mice after dietary administration of the test substance for 28 days. The study is considered valid and in compliance with GLP and the guideline US-EPA-OPPTS Series 870, Health Effects Testing Guidelines, N°870.6300.
The administered doses were 30, 100 and 300 ppm. Cyclophosphamide served as a positive control and proved the sensibility of the test system. Under the conditions of the study, the dietary NOAEL for systemic toxicity and immunotoxicity was set at 300 ppm (49 mg/kg bw/day), the highest dose level tested, since no adverse effects were observed up to and including this dose level.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 49 mg/kg bw/day
- Study duration:
- subacute
- Species:
- mouse
- Quality of whole database:
- U.S. EPA test guideline and GLP study, fulfilling the criteria of suitability as key study.
Effect on immunotoxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Effect on immunotoxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Mode of Action Analysis / Human Relevance Framework
No data available.
Additional information
The potential immunotoxicity of the test substance was assessed in male C57BL mice according to an U.S. EPA test guideline, under GLP conditions. This study is considered suitable as key study (M-410294-01-1, 2011). Groups of 10 C57BL mice rats/per dose were exposed daily via the diet to 30, 100 and 300 ppm test item, corresponding to 5, 16 and 49 mg/kg bw/day (mean ratios) of the test substance for at least 28 days. The dosing solutions were prepared by mixing the appropriate amounts of the test substance with the diet. The control group received the plain diet only. One group of rats received 7.5 mg/kg bw Cyclophosphamide as a positive control for immunosuppression. Cyclophosphamide was administered solubilized in deionized water via gavage. Both the concentration and homogeneity of the test substance in the diet and the positive control in the vehicle were analyzed and considered valid. Clinical signs were recorded daily and body weight and food consumption were measured weekly. A detailed physical examination was performed weekly throughout the study. On Day 26, rats were injected in the tail vein with a 0.1 mL preparation of Sheep Red Blood Cells (SRBC), containing 1 x 10^9 cells/mL. Four days after SRBC immunization, blood was taken from all animals (non-fasted) and analyzed for anti SRBC- IgM using an ELISA kit. When animals were sacrificed on Day 30, the gross necropsy included the examination of all major organs, tissues and body cavities. Macroscopic abnormalities were recorded but not sampled. The organ weight was recorded for spleen and thymus. No mortality was observed in the study. There were no treatment-related signs observed in the treatment groups and positive control group. Body weight and feed consumption were not affected by treatment with the test substance or the positive control as compared to the vehicle control. One animal in the 30 ppm group showed body weight loss between study days 22 and 29. This was considered not to be treatment-related as it was not found in any other animal. No differences regarding gross pathology or organ weights were found between treatment and control groups at necropsy. The SRBC response was unchanged in treatment groups compared to control groups. In the positive control group, the concentration of anti-SRBC IgM was 76% lower than the controls. Spleen and thymus were smaller and lighter than in vehicle control animals and atrophic/small spleen and/or thymus were noted (7/10 and 8/10 animals, respectively). With these results, the positive control cyclophosphamide confirmed the sensitivity of the test system. No immunotoxic properties were noted in male mice at doses of test item up to and including 300 ppm, corresponding to 49 mg/kg bw/day.
Under the conditions of the study, the NOAEL for immunotoxicity and systemic toxicity was set to 49 mg/kg bw/day (the highest administered dose).
Justification for classification or non-classification
The available data on immunotoxicity of the test substance do not meet the criteria for classification according to Regulation (EC) 1272/2008, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.